Concurrent Session 10: Cartilage Repair & Regenerative Medicine

Intra-articular Drug Delivery in OA

Date/Time: Saturday, May 4, 2019 - 2:00 PM to 3:30 PM
Log in to Add to My Schedule


Intra-articular Drug Delivery in OA
Laura Creemers, PhD UMC Utrecht

Local biomaterial-based delivery offers many advantages for diseases that are local in nature. High and effective local concentrations can be attained for a longer period of time. Additionally, the systemic burden is low, hence offering a new lease of life to drugs that are effective but have unacceptable systemic side effects. As the drug is delivered and retained locally, smaller amounts of the drug are needed which has the potency of greatly reducing the costs of expensive biologicals-based treatments, such as antibodies and recombinant growth factors. Osteoarthritis (OA), through  inflammation and  chronic pain the number 5 cause of loss of disability-adjusted life years (DALYs) in the Western world, is such a local disease and is amenable to such strategies.

As pain is a major clinical symptom of OA, delivery of anti-inflammatory drugs (AID) is the most obvious application. The only product currently on the market is a microsphere platform that delivers a corticosteroid. With another well known AID, celecoxib,  we achieved very promising results, also in intervertebral disc degeneration leading to spine OA. Delivery of regenerative agents will be the future goal, although first truly active compounds should be identified. Efficient development of effective drug delivery systems of the future will in adddition heavily depend on an interdisciplinary approach including pharmacokinetics, advanced in vivo imaging, mass spectrometry imaging, biomaterial design and of course cartilage (patho)biology.

Followed by select abstract presentations.